🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Alignment Healthcare director sells shares worth over $250,000

Published 07/19/2024, 08:28 PM
ALHC
-

Joseph S. Konowiecki, a director at Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold a total of 25,000 shares of the company's common stock, transactions valued at over $250,000. The sales occurred on July 17, 2024, with share prices ranging from $10.00 to $10.01.

The sale was part of a series of transactions on the same day, signaling a notable change in Konowiecki's holdings in the company. Following the sales, Konowiecki still owns a substantial number of shares, with his stake in the company standing at 1,208,221 shares of common stock.

The transactions were promptly disclosed in a regulatory filing with the Securities and Exchange Commission. Investors often monitor insider sales as they can provide insights into an insider’s perspective on the value of the company's stock.

Alignment Healthcare, Inc., headquartered in Orange, California, operates in the hospital and medical service plans industry. As with any insider transaction, the recent sales by Konowiecki have been made public to ensure transparency and maintain investor confidence in the market dealings related to the company.

Investors in Alignment Healthcare can continue to follow the company's insider transactions, which are regularly filed and available to the public, to understand better how the actions of its directors and executives may reflect their views on the company's current valuation and future prospects.

In other recent news, Alignment Healthcare has reported significant growth in its Q1 2024 earnings, with a 50% increase in health plan membership and a 43% rise in total revenue. The company's adjusted EBITDA was better than anticipated, despite being negative. As a result, the company is raising its full-year guidance and targeting at least a 20% increase in health plan membership and margin expansion in 2025.

In addition to financial developments, Alignment Healthcare has also amended its corporate charter to include a provision limiting the liability of certain officers. This change aligns with Delaware state law and was approved by the company's stockholders during their annual meeting. Other notable decisions from the meeting include the election of four Class III directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

Furthermore, the company's stock has been upgraded by both BofA Securities and Piper Sandler. BofA Securities upgraded the stock from Neutral to Buy and increased the price target to $11.00, citing improved visibility into the company's margin progression. Similarly, Piper Sandler upgraded the stock from Neutral to Overweight, following the company's robust Q1 results and revised full-year 2024 guidance. The new price target of $8.00 is based on a 25-fold multiple applied to the company's projected higher adjusted EBITDA for the 2026 calendar year. These are all recent developments in Alignment Healthcare's operations.

InvestingPro Insights

As investors digest the news of Joseph S. Konowiecki's recent stock sales in Alignment Healthcare, Inc. (NASDAQ:ALHC), it's crucial to consider the company's financial health and market performance. According to real-time data from InvestingPro, Alignment Healthcare has a market capitalization of $1.92 billion and has experienced notable revenue growth over the last twelve months as of Q1 2024, with an increase of 31.76%. Despite this growth, the company's gross profit margin stands at 10.61%, highlighting a potential area of concern for profitability.

The stock's performance has been strong, with a one-month price total return of 42.03% and a three-month return of 93.65%, which might explain Konowiecki's decision to capitalize on recent gains. However, InvestingPro Tips suggest caution; two analysts have recently revised their earnings predictions downwards for the upcoming period, and the stock is currently in overbought territory according to the Relative Strength Index (RSI).

Investors considering ALHC should be aware that the company is not expected to be profitable this year, and it has been trading near its 52-week high. With the stock's significant return over the last week and a high Price/Book multiple of 14.71, market participants may want to explore further insights and metrics. For a deeper dive into Alignment Healthcare's performance and additional InvestingPro Tips, visit https://www.investing.com/pro/ALHC. There, users can find even more expert analysis and tips – currently, there are 11 additional tips available. To get the most out of these insights, use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.